Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conatus Pharmaceuticals CNAT

Healthcare Biotechnology
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes... see more

Recent & Breaking News (NDAQ:CNAT)

Histogen Reports Second Quarter 2021 Earnings and Provides Business Update

GlobeNewswire August 11, 2021

Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference

GlobeNewswire July 29, 2021

Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021

GlobeNewswire July 28, 2021

Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration

GlobeNewswire June 30, 2021

Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

GlobeNewswire June 22, 2021

Histogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire June 9, 2021

Histogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire June 7, 2021

Histogen Provides Update on its Development Programs and Pipeline Focus

GlobeNewswire June 3, 2021

Histogen and Amerimmune Report Publication on Emricasan in COVID-19

GlobeNewswire May 19, 2021

Histogen Reports First Quarter 2021 Earnings and Provides Business Update

GlobeNewswire May 13, 2021

Histogen to Report Second Quarter 2021 Financial Results and Provide Business Update

GlobeNewswire April 28, 2021

Histogen to Present at the 20th Annual Needham Virtual Healthcare Conference

GlobeNewswire March 30, 2021

Histogen Appoints Rochelle Fuhrmann to Board of Directors

GlobeNewswire March 25, 2021

Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients

GlobeNewswire March 16, 2021

Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration

GlobeNewswire March 15, 2021

Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

GlobeNewswire March 11, 2021

Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham-Bannister, Ph.D.

GlobeNewswire March 10, 2021

Histogen to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update

GlobeNewswire March 4, 2021

Histogen to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

GlobeNewswire March 2, 2021

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

GlobeNewswire February 16, 2021